- Home
- EDIT
EDIT
Editas Medicine Inc.
as 12-20-2024 3:35pm EST
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 176.7M | IPO Year: | 2016 |
| Target Price: | $8.08 | AVG Volume (30 days): | 3.1M |
| Analyst Decision: | Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.56 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.28 - $11.58 | Next Earning Date: | 11-04-2024 |
| Revenue: | $61,759,000 | Revenue Growth: | 150.95% |
| Revenue Growth (this year): | -53.95% | Revenue Growth (next year): | -62.56% |
Stock Insider Trading Activity of Editas Medicine Inc. (EDIT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| O'Neill Gilmore Neil | EDIT | CEO | Dec 3 '24 | Sell | $2.08 | 1,618 | $3,361.23 | 312,106 | |
| Mei Baisong | EDIT | EVP, CHIEF MEDICAL OFFICER | Dec 3 '24 | Sell | $2.08 | 541 | $1,123.77 | 133,354 |
Latest Editas Medicine Inc. News
EDIT Breaking Stock News: Dive into EDIT Ticker-Specific Updates for Smart Investing
Zacks
5 days ago
EDIT Stock Falls on Decision to End Reni-Cel Studies, Cut Workforce
MT Newswires
5 days ago
JPMorgan Downgrades Editas Medicine to Underweight From Neutral
TipRanks
7 days ago
Editas Medicine price target lowered to $8 from $10 at Baird
Investing.com
8 days ago
Brokerages downgrade gene editing company Editas to 'hold', shares slump 23%
GuruFocus.com
8 days ago
Editas Medicine Reshapes Future with In Vivo Focus Amid Major Workforce Cuts
MT Newswires
8 days ago
JonesTrading Downgrades Editas Medicine to Hold From Buy
MT Newswires
8 days ago
Stifel Downgrades Editas Medicine Hold From Buy, Adjusts Price Target to 3 From $11
MT Newswires
8 days ago
Truist Securities Downgrades Editas Medicine Hold From Buy
Compare EDIT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EDIT Editas Medicine Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.